Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 10, 2022 07:00 ET | Source: Atea Pharmaceuticals, Inc.

Atea Pharmaceuticals Appoints Nancy Gail Berry Agrawal, Ph.D., as Executive Vice President of Preclinical Development

BOSTON, Feb. 10, 2022 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company engaged in the discovery and development of oral direct acting therapeutics for...
February 09, 2022 07:00 ET | Source: Atea Pharmaceuticals, Inc.

Atea Pharmaceuticals to Present at 11th Annual SVB Leerink Global Healthcare Conference

BOSTON, Feb. 09, 2022 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral direct...
February 02, 2022 07:00 ET | Source: Atea Pharmaceuticals, Inc.

Atea Pharmaceuticals Announces Publication of Data Supporting Bemnifosbuvir’s (AT-527) Novel Mechanism of Action Against SARS-CoV-2 in Nature Communications

BOSTON, Feb. 02, 2022 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company, today announced that new data highlighting bemnifosbuvir...
January 07, 2022 07:00 ET | Source: Atea Pharmaceuticals, Inc.

Atea Pharmaceuticals Highlights Strategic Priorities for 2022

COVID-19: Planning global Phase 2 outpatient trial for bemnifosbuvir (AT-527) designed to support anticipated combination trials HCV: Obtained from Merck an exclusive worldwide license to ruzasvir...
January 03, 2022 07:00 ET | Source: Atea Pharmaceuticals, Inc.

Atea Pharmaceuticals to Present at 40th Annual J.P. Morgan Healthcare Conference

BOSTON, Jan. 03, 2022 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company, today announced that Jean-Pierre Sommadossi, PhD, Chief...
December 17, 2021 07:00 ET | Source: Atea Pharmaceuticals, Inc.

Atea Pharmaceuticals Added to the Nasdaq Biotechnology Index

BOSTON, Dec. 17, 2021 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company, today announced that the company has been added to the...
December 14, 2021 16:30 ET | Source: Atea Pharmaceuticals, Inc.

Atea Pharmaceuticals Introduces New Strategic Clinical Development Program for AT-527 in COVID-19

Responding to the rapidly evolving SARS-CoV-2, emerging variants and changing treatment landscape, Atea is updating the development strategy for AT-527 In addition to monotherapy evaluation,...
November 22, 2021 07:00 ET | Source: Atea Pharmaceuticals, Inc.

Atea Pharmaceuticals to Present at the 4th Annual Evercore ISI HealthCONx Conference

BOSTON, Nov. 22, 2021 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company, today announced that Jean-Pierre Sommadossi, PhD, Chief...
November 16, 2021 16:30 ET | Source: Atea Pharmaceuticals, Inc.

Atea Pharmaceuticals Provides Update on Strategic Collaboration with Roche

BOSTON, Nov. 16, 2021 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company, today announced that the strategic collaboration pursuant to...
November 11, 2021 16:01 ET | Source: Atea Pharmaceuticals, Inc.

Atea Pharmaceuticals Provides Clinical and Corporate Update and Reports Third Quarter 2021 Financial Results

Phase 3 MORNINGSKY Protocol Amendment to Include New Primary Endpoint, Refined Patient Population and Increased Dose, with Plan to Accelerate Completion of Enrollment Infectious Virus Data...